Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 19/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.64 |
| ▸ | MTOR | P42345 | 16/20 | 0.64 |
| ▸ | ATR | Q13535 | 4/20 | 0.64 |
| ▸ | PRKDC | P78527 | 2/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19618853 | 1.00 | ATM (0.64) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL20006294 | 0.84 | ATM (0.62) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL17242588 | 0.78 | ATM (1.00) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL17246304 | 0.78 | ATM (1.00) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL17246341 | 0.78 | ATM (1.00) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL23615859 | 0.76 | ATM (0.55) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL24381740 | 0.76 | ATM (0.68) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL24381793 | 0.74 | ATM (0.73) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL17272550 | 0.74 | ATM (0.91) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL17272539 | 0.74 | ATM (0.91) | ATMPIK3CAMTORATRPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3140303-B1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-03-28 | — | — | EP | disclosed |